IDEAL-CRT: A Phase 1/2 Trial of Isotoxic Dose-Escalated Radiation Therapy and Concurrent Chemotherapy in Patients With Stage II/III Non-Small Cell Lung Cancer

PURPOSE: To report toxicity and early survival data for IDEAL-CRT, a trial of dose-escalated concurrent chemoradiotherapy (CRT) for non-small cell lung cancer. PATIENTS AND METHODS: Patients received tumor doses of 63 to 73 Gy in 30 once-daily fractions over 6 weeks with 2 concurrent cycles of cispl...

Descripción completa

Detalles Bibliográficos
Autores principales: Landau, David B., Hughes, Laura, Baker, Angela, Bates, Andrew T., Bayne, Michael C., Counsell, Nicholas, Garcia-Alonso, Angel, Harden, Susan V., Hicks, Jonathan D., Hughes, Simon R., Illsley, Marianne C., Khan, Iftekhar, Laurence, Virginia, Malik, Zafar, Mayles, Helen, Mayles, William Philip M., Miles, Elizabeth, Mohammed, Nazia, Ngai, Yenting, Parsons, Emma, Spicer, James, Wells, Paula, Wilkinson, Dean, Fenwick, John D.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier Science Inc 2016
Materias:
Clinical Investigation
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4959796/
https://www.ncbi.nlm.nih.gov/pubmed/27296040
http://dx.doi.org/10.1016/j.ijrobp.2016.03.031

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4959796/
https://www.ncbi.nlm.nih.gov/pubmed/27296040
http://dx.doi.org/10.1016/j.ijrobp.2016.03.031

Ejemplares similares